This approval is expected to help in treatment of persistent AFib and for RF ablation of CTI dependent atrial flutter.
Medtronic received FDA approval for the Affera mapping and ablation system and Sphere-9 catheter, which can deliver both PFA ...
Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced United States Food and Drug ...
Medtronic (MDT) announced FDA approval of the Affera Mapping and Ablation System with Sphere-9 Catheter, an all-in-one, high-density mapping ...
Medtronic said the Food and Drug Administration approved its Affera mapping and ablation system with sphere-9 catheter.
Medtronic (NYSE: MDT) announced today that the FDA approved an early feasibility study to evaluate its Affera system for ...
Highly anticipated by electrophysiologists for its innovation and demonstrated safety and efficacy as well as improved workflow and short learning curve Now with two pulsed field ablation (PFA) ...
Medtronic has announced US Food and Drug Administration (FDA) approval to conduct an early feasibility study using the Affera ...
Medtronic plc received U.S. FDA approval to undertake an early feasibility study of its dual-energy Affera cardiac ablation system in sustained ventricular tachycardia. Affera combines both ...
Medtronic has received Food and Drug Administration approval to study its Affera mapping and ablation system and Sphere-9 catheter to treat sustained ventricular tachycardia, an abnormal rhythm of the ...